Treatment Profile And Insulin Dose as a Factor Impacting Glycaemia Control Among Premix Insulin Users with T2DM in China
Value Health
.
2014 Nov;17(7):A720.
doi: 10.1016/j.jval.2014.08.012.
Epub 2014 Oct 26.
Authors
L Liu
1
,
Y Chen
2
,
L Gu
2
,
B H Curtis
2
,
S M Babineaux
3
Affiliations
1
Eli Lilly Suzhou Pharmaceutical Co. Ltd., Shanghai, China.
2
Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China.
3
Eli Lilly and Company, Carmel, IN, USA.
PMID:
27202552
DOI:
10.1016/j.jval.2014.08.012
No abstract available